Vaxeal’s cancer vaccine candidates
Together they cover over 80% of all the major solid tumour types, and are also major targets in haematological malignancies, enabling our cancer vaccine to be indicated to a wide spectrum of cancers.
More information...
Hepatitis C Program improves efficacy
Our strategy consists to combine our vaccine with inhibitors to optimize cross-reactivity with natural variants.
More information...
Situation of therapeutic vaccines
The vaccines in development cover more than 70 different conditions. Vaccines for cancer and infectious diseases account for 55% and 24% of the vaccines in the pipeline respectively.
More information...Upcoming Events
|
May 19-24, 2013: Vaxeal will attend the international congress on Meningeal disease vaccines in Varadero (Cuba). Ahmed Bouzidi will present an overview on the latest clinical developments on Meningeal disease vaccines. Read more... |
|
May 29-31, 2013: Vaxeal will attend the Sino-Euro Bio-partnering in Shanghai (China). Ahmed Bouzidi will give a key-note speech on EU life science industry. Read more... |
Overview
The company has developed a novel therapeutic vaccine strategy.
Read more...
Pipeline
Vaxeal is building a pipeline of oncology and infectious disease immunotherapy candidates.
Read more...
Breakthrough Science
Vaxeal’s mission is to develop therapeutic vaccines to improve survival rates and quality of life.
Read more...
Latest News & Events
At Vaxeal, the patient is at the core of what we do.
Please read our latest news
Headquarters
Address:
Vaxeal Holding SA
Avenue Paul Cérésole 24
1800 Vevey - Switzerland
Phone:
+41 21 977 3000
Fax :
+41 21 922 1000
International Offices
Vaxeal Research SAS
Genopoles Entreprises
4 Rue Pierre Fontaine
91058 Evry Cedex - France
Phone: +33 1 60 87 89 31
Fax: +33 1 60 87 89 99
Vaxeal IP Management Sàrl
Avenue de Tivoli 3
1700 Fribourg - Switzerland
Phone: +41 26 322 1212
Fax: +41 26 322 2554
Vaxeal China Inc.
bioBay, 218 Xing Hu Road,
A2 Building, Suite 214,
Suzhou Industrial Park,
Suzhou 215125 - China
Phone: +86 150 624 10 505
Fax: +86 512 629 566 33